Zhu Jinsheng, Yang Lei, Jia Yangfan, Balistrieri Angela, Fraidenburg Dustin R, Wang Jian, Tang Haiyang, Yuan Jason X-J
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangdong Key Laboratory of Vascular Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
College of Veterinary Medicine, Northwest A&F University, Yangling, China.
JACC Asia. 2022 Dec 15;2(7):787-802. doi: 10.1016/j.jacasi.2022.09.010. eCollection 2022 Dec.
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease. Sustained pulmonary vasoconstriction and concentric pulmonary vascular remodeling contribute to the elevated pulmonary vascular resistance and pulmonary artery pressure in PAH. Endothelial cells regulate vascular tension by producing endothelium-derived relaxing factors (EDRFs) and endothelium-derived contracting factors (EDCFs). Homeostasis of EDRF and EDCF production has been identified as a marker of the endothelium integrity. Impaired synthesis or release of EDRFs induces persistent vascular contraction and pulmonary artery remodeling, which subsequently leads to the development and progression of PAH. In this review, the authors summarize how EDRFs and EDCFs affect pulmonary vascular homeostasis, with special attention to the recently published novel mechanisms related to endothelial dysfunction in PAH and drugs associated with EDRFs and EDCFs.
肺动脉高压(PAH)是一种进行性致命疾病。持续性肺血管收缩和向心性肺血管重塑导致PAH患者肺血管阻力升高和肺动脉压力升高。内皮细胞通过产生内皮源性舒张因子(EDRFs)和内皮源性收缩因子(EDCFs)来调节血管张力。EDRF和EDCF产生的稳态已被确定为内皮完整性的标志物。EDRFs合成或释放受损会导致持续性血管收缩和肺动脉重塑,进而导致PAH的发生和发展。在这篇综述中,作者总结了EDRFs和EDCFs如何影响肺血管稳态,特别关注最近发表的与PAH内皮功能障碍相关的新机制以及与EDRFs和EDCFs相关的药物。